<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03564275</url>
  </required_header>
  <id_info>
    <org_study_id>2017-1091</org_study_id>
    <nct_id>NCT03564275</nct_id>
  </id_info>
  <brief_title>Proton Boost in Prostate Cancer</brief_title>
  <official_title>Assessing the Effectiveness of Photon Therapy With a Proton Therapy Boost in the Treatment of Prostate Cancer as Compared to Photon Therapy Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study uses photon radiation with a proton boost to treat prostate cancer. The purpose of
      this study is to determine if proton therapy as a boost following photon intensity modulated
      radiation therapy (IMRT) produces decreased toxicity as compared to conventional photon IMRT
      alone in the treatment of prostate cancer. Our secondary objective is to determine the
      effectiveness of this treatment regimen. Effectiveness will be determined by length of time
      to progression or recurrence of disease and overall survival. Patients on this study will be
      treated with a course of photon radiation therapy followed by a boost course of proton
      radiation.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">April 16, 2018</start_date>
  <completion_date type="Anticipated">April 2033</completion_date>
  <primary_completion_date type="Anticipated">April 2033</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Matched pair analysis. Each prospective patient will be matched with two historical patients based on the inclusion, exclusion and match criteria.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hematuria - Change from baseline</measure>
    <time_frame>Post therapy - 1, 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54, 60 months, 6,7,8,9,10 years</time_frame>
    <description>Common Terminology Criteria for Adverse Events - Hematuria Scale - 1(least severe) - 5 (most severe)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary Incontinence - Change from baseline</measure>
    <time_frame>Post therapy - 1, 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54, 60 months, 6,7,8,9,10 years</time_frame>
    <description>Common Terminology Criteria for Adverse Events - Urinary Incontinence Scale - 1(least severe) - 3 (most severe)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dysuria - Change from baseline</measure>
    <time_frame>Post therapy - 1, 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54, 60 months, 6,7,8,9,10 years</time_frame>
    <description>Presence or Absence</description>
  </primary_outcome>
  <primary_outcome>
    <measure>International Prostate Symptom Score - Change from baseline</measure>
    <time_frame>Post therapy - 1, 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54, 60 months, 6,7,8,9,10 years</time_frame>
    <description>Records patient reported urinary symptoms - Scale 1-35 - 1-7 Mild symptoms, 8-19 Moderate symptoms, 20-35 Severe symptoms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rectal Bleeding - Change from baseline</measure>
    <time_frame>Post therapy - 1, 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54, 60 months, 6,7,8,9,10 years</time_frame>
    <description>Common Terminology Criteria for Adverse Events - Rectal Hemorrhage Scale - 1(least severe) - 5 (most severe)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Erectile Dysfunction - Change from baseline</measure>
    <time_frame>Post therapy - 1, 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54, 60 months, 6,7,8,9,10 years</time_frame>
    <description>Common Terminology Criteria for Adverse Events - Erectile Dysfunction Scale - 1(least severe) - 3 (most severe)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Monitored for 10 years after completion of radiation therapy</time_frame>
    <description>Measured by time to cancer recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Monitored for 10 years after completion of radiation therapy</time_frame>
    <description>Measured by time to cancer-related death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Cancer of the Prostate</condition>
  <arm_group>
    <arm_group_label>Prospective Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Proton Boost</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Retrospective Comparison Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Retrospective patients previously treated with standard of care photon therapy. There is no patient interaction with this group. Data collection from medical records only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Proton Boost</intervention_name>
    <description>13-15 treatments with proton therapy given as a boost to standard of care photon therapy</description>
    <arm_group_label>Prospective Treatment Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥18 years of age

          -  Diagnosis of low risk prostate cancer (T1c-T2a, Gleason 6, Prostate Specific Antigen
             (PSA) &lt;10) -OR-

          -  Diagnosis of intermediate risk prostate cancer (T1c-T2c, Gleason 7 and/or PSA 10- 20)

          -  Life expectancy &gt;10 yrs

          -  Physically and mentally capable of signing the consent form of their own volition

        Exclusion Criteria:

          -  &lt; 18 years of age

          -  Diagnosis of high risk prostate cancer (T3 or higher, Gleason &gt;7 and/or PSA &gt;20)

          -  Current or historical use of androgen deprivation therapy

          -  Nodal positivity

          -  Previous cancer excluding non-melanoma skin cancer

          -  History of prostatectomy

          -  History of brachytherapy for prostate cancer

          -  Life expectancy &lt;10 yrs

          -  Physically or mentally incapable of signing the consent form of their own volition
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Barrett, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Boccon-Gibod LM, Dumonceau O, Toublanc M, Ravery V, Boccon-Gibod LA. Micro-focal prostate cancer: a comparison of biopsy and radical prostatectomy specimen features. Eur Urol. 2005 Dec;48(6):895-9.</citation>
    <PMID>16125298</PMID>
  </reference>
  <reference>
    <citation>Gregori A, Vieweg J, Dahm P, Paulson DF. Comparison of ultrasound-guided biopsies and prostatectomy specimens: predictive accuracy of Gleason score and tumor site. Urol Int. 2001;66(2):66-71.</citation>
    <PMID>11223746</PMID>
  </reference>
  <reference>
    <citation>Scales CD, Amling CL, Kane CJ, et al. Can unilateral Prostate Cancer be Reliably Predicted Based Upon Biopsy Features? J Urol. 2006; 175:373.</citation>
  </reference>
  <reference>
    <citation>Schulte RT, Wood DP, Daignault S, Shah RB, Wei JT. Utility of extended pattern prostate biopsies for tumor localization: pathologic correlations after radical prostatectomy. Cancer. 2008 Oct 1;113(7):1559-65. doi: 10.1002/cncr.23781.</citation>
    <PMID>18726951</PMID>
  </reference>
  <reference>
    <citation>Arrayeh E, Westphalen AC, Kurhanewicz J, Roach M 3rd, Jung AJ, Carroll PR, Coakley FV. Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study. Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):e787-93. doi: 10.1016/j.ijrobp.2011.11.030. Epub 2012 Feb 11.</citation>
    <PMID>22331003</PMID>
  </reference>
  <reference>
    <citation>Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, von Eschenbach AC, Kuban DA, Rosen I. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1097-105.</citation>
    <PMID>12128107</PMID>
  </reference>
  <reference>
    <citation>Peeters ST, Heemsbergen WD, Koper PC, van Putten WL, Slot A, Dielwart MF, Bonfrer JM, Incrocci L, Lebesque JV. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006 May 1;24(13):1990-6.</citation>
    <PMID>16648499</PMID>
  </reference>
  <reference>
    <citation>Andrzejewski P, Kuess P, Knäusl B, Pinker K, Georg P, Knoth J, Berger D, Kirisits C, Goldner G, Helbich T, Pötter R, Georg D. Feasibility of dominant intraprostatic lesion boosting using advanced photon-, proton- or brachytherapy. Radiother Oncol. 2015 Dec;117(3):509-14. doi: 10.1016/j.radonc.2015.07.028. Epub 2015 Sep 6.</citation>
    <PMID>26349588</PMID>
  </reference>
  <reference>
    <citation>Bossart EL, Stoyanova R, Sandler K, Studenski M, Orman A, Abramowitz M, Pollack A. Feasibility and Initial Dosimetric Findings for a Randomized Trial Using Dose-Painted Multiparametric Magnetic Resonance Imaging-Defined Targets in Prostate Cancer. Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):827-34. doi: 10.1016/j.ijrobp.2016.01.052. Epub 2016 Feb 4.</citation>
    <PMID>27020109</PMID>
  </reference>
  <reference>
    <citation>Johansson S, Aström L, Sandin F, Isacsson U, Montelius A, Turesson I. Hypofractionated proton boost combined with external beam radiotherapy for treatment of localized prostate cancer. Prostate Cancer. 2012;2012:654861. doi: 10.1155/2012/654861. Epub 2012 Jul 8.</citation>
    <PMID>22848840</PMID>
  </reference>
  <reference>
    <citation>Nihei K, Ogino T, Ishikura S, Kawashima M, Nishimura H, Arahira S, Onozawa M. Phase II feasibility study of high-dose radiotherapy for prostate cancer using proton boost therapy: first clinical trial of proton beam therapy for prostate cancer in Japan. Jpn J Clin Oncol. 2005 Dec;35(12):745-52. Epub 2005 Nov 28.</citation>
    <PMID>16314345</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 18, 2018</study_first_submitted>
  <study_first_submitted_qc>June 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2018</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>William Barrett</investigator_full_name>
    <investigator_title>Director, University of Cincinnati Cancer Institute Medical Director, Charles M. Barrett Cancer Center Professor and Chairman, Radiation Oncology University of Cincinnati</investigator_title>
  </responsible_party>
  <keyword>Radiation Therapy</keyword>
  <keyword>Proton Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

